LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Затворен

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Ключови измерители
By Trading Economics
Приходи	6.8M -8.1M
Продажби	33M 72M
EPS	-0.04
Марж на печалбата	-11.242
Служители	105
EBITDA	6.7M -5.4M

Дивиденти
By Dow Jones
Следващи печалби	19.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	55M 146M
Предишно отваряне	0
Предишно затваряне	0

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.02.2026 г., 23:26 ч. UTC

Значими двигатели на пазара

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10.02.2026 г., 22:31 ч. UTC

Печалби

Correction to America Movil 4Q Profit Article

10.02.2026 г., 22:22 ч. UTC

Печалби

America Movil 4Q Profit Jumps on Lower Financial Costs

10.02.2026 г., 23:51 ч. UTC

Пазарно говорене

Печалби

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10.02.2026 г., 23:42 ч. UTC

Пазарно говорене

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Печалби

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10.02.2026 г., 23:21 ч. UTC

Пазарно говорене

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10.02.2026 г., 23:21 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

10.02.2026 г., 22:17 ч. UTC

Пазарно говорене

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10.02.2026 г., 22:15 ч. UTC

Печалби

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10.02.2026 г., 22:10 ч. UTC

Печалби

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10.02.2026 г., 22:10 ч. UTC

Печалби

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10.02.2026 г., 22:09 ч. UTC

Печалби

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10.02.2026 г., 22:09 ч. UTC

Печалби

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10.02.2026 г., 22:01 ч. UTC

Печалби

Intact Financial 4Q EPS C$5.24 >IFC.T

10.02.2026 г., 21:54 ч. UTC

Печалби

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10.02.2026 г., 21:53 ч. UTC

Печалби

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10.02.2026 г., 21:51 ч. UTC

Печалби

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10.02.2026 г., 21:51 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10.02.2026 г., 21:50 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10.02.2026 г., 21:50 ч. UTC

Печалби

James Hardie Industries 3Q EPS 12c >JHX

10.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

10.02.2026 г., 21:50 ч. UTC

Печалби

James Hardie Industries 3Q Adj EPS 24c >JHX

10.02.2026 г., 21:49 ч. UTC

Печалби

James Hardie Industries 3Q Sales $1.24B >JHX

10.02.2026 г., 21:49 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.